Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Novavax (NVAX – Research Report). The associated price target is $11.00.
Mayank Mamtani’s rating is based on a multitude of factors, including Novavax’s recent settlement with GAVI, which has favorably resolved a significant financial uncertainty for the company. This agreement not only eases near-term cash flow concerns but also paves the way for the potential removal of ‘going concern’ language, reflecting improved financial health. Additionally, Mamtani acknowledges the impact of cost-reduction strategies that Novavax has implemented, which are expected to significantly lower operational expenses and exceed initial reduction targets. These measures, alongside the anticipated focus on the fall 2024-25 COVID vaccination season and the progression of their COVID-Influenza Combination (CIC) vaccine, contribute to the Buy rating.
Furthermore, the anticipation of the COVID-Influenza Combo vaccine becoming a significant part of the U.S. commercial market, especially for the population over 65 years old, leads to a positive outlook for Novavax’s market position. The reduction in competition within this demographic and the potential dominance of the CIC vaccine offering bolster confidence in the company’s future revenue streams. The planned optimization of their vaccine rollout for the upcoming seasons and the lowering of operational expenses by a remarkable 56% compared to 2022 are key factors that underpin Mamtani’s Buy recommendation for Novavax’s stock.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Novavax (NVAX) Company Description:
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
- Novavax Settles with Gavi, Commits to Equitable Vaccine Pricing
- Novavax Stock (NASDAQ:NVAX): Too Much Bad News Can Fuel a Reversal
- Novavax announces results from Phase 3 trial of R21/Matrix-M malaria
- Novavax Announces Workforce Reduction to Cut Costs
- Novavax to reduce current total global workforce by about 12%
